

# Signe Stensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/126150/publications.pdf>

Version: 2024-02-01

15  
papers

402  
citations

933447

10  
h-index

1058476

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

440  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1882-1887.	4.4	5
2	Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (<scp>GIP</scp> receptor antagonist <scp>GIP</scp>(3&#30)<scp>NH<sub>2</sub></scp> on <scp>GIP</scp> actions in humans. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 68-74.	4.4	14
3	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. <i>European Journal of Endocrinology</i> , 2021, 184, 383-394.	3.7	15
4	Effects of endogenous GIP in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2021, 185, 33-45.	3.7	21
5	GIP and the gut-bone axis â€“ Physiological, pathophysiological and potential therapeutic implications. <i>Peptides</i> , 2020, 125, 170197.	2.4	25
6	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. <i>Peptides</i> , 2020, 125, 170183.	2.4	61
7	GIPâ€™s involvement in the pathophysiology of type 2 diabetes. <i>Peptides</i> , 2020, 125, 170178.	2.4	18
8	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. <i>Bone</i> , 2020, 140, 115553.	2.9	25
9	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e725-e738.	3.6	37
10	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. <i>Diabetes</i> , 2019, 68, 906-917.	0.6	118
11	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.6	10
12	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. <i>Diabetes</i> , 2018, 67, 145-OR.	0.6	3
13	Awareness of human papillomavirus after introduction of HPV vaccination: a large population-based survey of Scandinavian women. <i>European Journal of Cancer Prevention</i> , 2017, 26, 170-178.	1.3	8
14	Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study. <i>International Journal of Cancer</i> , 2016, 138, 361-368.	5.1	41
15	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. <i>Diabetes</i> , 0, , .	0.6	1